Sparrow Pharmaceuticals

Nearly 2 million Americans are on long-term corticosteroid therapy to treat diseases such as rheumatoid arthritis, asthma, vasculitis, and blood cancers. To control their disease those patients face the high adverse effects risk of corticosteroids. Drug adverse effects, of which corticosteroids are responsible for 10%, cost up to $30B per year in the US.

Sparrow Pharmaceuticals is developing safer corticosteroids. Those will provide patients a new standard of care that is effective, safe, cost-effective, and convenient. A tablet form will start Phase 2 clinical trials in 2019. Other forms, such as ocular, topical, and inhaled, can also be developed utilizing the same patented technology.

Company Details